NCT05982301View on ClinicalTrials.gov

Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

February 9, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2025

Conditions
Gastric CancerChemotherapy EffectImmune Checkpoint Inhibitor
Interventions
DRUG

Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU

The study has only one arm. Sintilimab 200mg d1 ivgtt+paclitaxel-albumin 125mg/m2 d1 ivgtt+oxaliplatin 85mg/m2 d1 ivgtt+5-FU 2.4g/m2 civ46h, q2w.

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER